Genomewide
Scan
The goal of PROGRESS is to understand why prostate
cancer runs in some families by uncovering the genes that cause
this disease.
The way we search for genes is called a genomewide scan. A genome
scan is the process of looking at many different signposts or
"markers" in the DNA to see if there are certain sections
of the genome that are associated with prostate cancer.
For example, if men with prostate cancer always inherit the same
sequence of DNA and men in the same family without prostate cancer
have not inherited that sequence of DNA, we would look more closely
to see if there is something about that sequence that may explain
why the men developed prostate cancer.
We are looking at nearly 400 markers in more than 2,000 people
to find patterns of DNA that may be associated with the disease.
We published our first genome scan findings in July 2000, based
on the first 94 completed families. A total of 253 families will
be included in our second genome scan analysis, to be completed
during 2001. We hope to have sufficient information in this larger
data set to identify additional regions that may contain hereditary
prostate cancer genes. |
|
|
Ongoing Follow-Up
One problem we have encountered when creating these
groups of families is that the information we collected from you
is several years old.
PROGRESS began collecting data in 1995, more than five
years ago! We know that in the last five years some of you have
had additional treatments for cancer and in some cases other family
members have been diagnosed with prostate cancer or another type
of cancer. Many of you have been kind enough to call us with updated
information.
To systematically update our information about you and your family,
we are preparing a follow-up survey. We will be mailing the follow-up
surveys during 2001 and 2002. The follow-up questionnaire will
include questions about your health and your family's health in
the last several years as well as other topics.
As always, your continued participation in PROGRESS is
entirely voluntary. We greatly appreciate the vast amount of information
you have already provided about your family. We hope that by continuing
our study and updating our information, we can eventually find
the genes that cause hereditary prostate cancer.
|
|
|
|
Stratified Analyses
In addition to our ongoing work on the genome scan,
we are using the data you provided in the PROGRESS questionnaire
to help us search for prostate cancer genes.
This is another way of finding genes by attempting to study subsets
of families that share similar characteristics. Because hereditary
prostate cancer probably involves several genes, it is common
to group or "stratify" families that may be more likely
to share the same gene. For example, in breast cancer research,
this approach was used to identify the gene called BRCA2. In a
large group of families with breast cancer, the researchers noticed
that a few families also had relatives diagnosed with ovarian
cancer. By studying the genetics of the smaller group of families
with both breast and ovarian cancer, the breast cancer researchers
were able to identify a gene that increases the risk of breast
cancer in some families.
We hope that by using the same technique and studying groups of
similar families, we will find the location of additional genes
for prostate cancer.
One way to group the PROGRESS families is by using medical
information collected when the prostate cancer was diagnosed.
In addition to completing the PROGRESS survey, men with
prostate cancer were asked to provide consent to allow us to access
their prostate-related medical records. We have collected copies
of medical records for those men who provided consent, and have
been working to summarize or "abstract" the data from
the records.
When a man is diagnosed with prostate cancer, the local pathologist
studies the prostate tissue from a biopsy or surgery using a microscope
to assign a grade to the cancer. Tumor grade reflects how abnormal
the cancer cells look compared to normal cells. The doctor also
determines the stage of disease, which reflects the spread of
the cancer _ that is, whether it is only in the prostate gland
or has spread to other areas of the body. Both the stage and the
grade are used to indicate how advanced the cancer is at diagnosis.
Though the stage and grade are not always a predictor of how quickly
the cancer will progress, it is one way to measure the severity
of the disease.
We plan to divide the PROGRESS families into groups with
more advanced and less advanced cancer to see if there are genetic
differences between the groups. We hope this will give us new
insights into the genes involved in the cancer process.
Another way to stratify families is by the presence of other cancers
in family members. You may recall that in 1999 we identified a
region or "locus" on chromosome one called CAPB that
was associated with prostate cancer in families who also had relatives
with brain cancer. This strategy of grouping families by using
other cancers has great potential to help us find prostate cancer
genes.
We are currently using the family information provided in your
questionnaires to find out which of the PROGRESS families
also have a relative(s) with breast cancer. The families with
both prostate cancer and breast cancer will be grouped together
and compared with families with prostate cancer who have no relatives
with breast cancer.
|
|
Prostate
Cancer
News Update
Since our last newsletter, the Mayo Clinic, located in Rochester,
MN, announced a fifth genetic region associated with prostate cancer
in families.
The locus is called HPC20, because it is located on chromosome 20.
The four other previously identified loci are HPC1, PCAP, and CAPB,
which are all located on chromosome 1, and HPCX, which is located
on the X chromosome. As with the other four, the HPC20 locus has
not yet been cloned. This means that a small part of chromosome
20 appears to be associated with prostate cancer in some families,
but it is not clear whether a prostate cancer gene is present at
that location.
Another recent development was reported by the University of Utah.
There is a newly cloned gene called HPC2, which appears to be associated
with prostate cancer in some people. These results are preliminary
and have not been confirmed in family studies such as PROGRESS.
Groups of researchers around the country are investigating the
recently reported genetic regions. We will keep you updated as new
information is available for all the reported genetic regions associated
with prostate cancer in families. |
Thank
You for Your Help!
In the last volume of our newsletter, we asked for information from
selected participants to be used to collect death certificates for
deceased men with prostate cancer.
Of the 128 people contacted, we have received 83% of the forms back.
If you did not get a form with your last newsletter, we did not
need your help. If you did receive a form and have not yet returned
it, it is not too late to send it back.
We have been sending out requests to each state or province for
copies of the death certificates. On the death certificate, we hope
to receive documentation of prostate cancer for certain deceased
relatives. This information is very valuable for our analysis and
we couldn't have done this without your help. |
|